Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
|Videos|March 22, 2021
Dr. Eric Klein on genomic testing for genitourinary cancers
Author(s)Urology Times staff
“It’s really fascinating how the field is expanding,” Klein says.
Advertisement
“[Genomic testing is] going to be a routine part of prostate cancer care and urologic cancer care going forward,” Eric A. Klein, MD, says in this video. Klein is the Chairman of the Glickman Urological & Kidney Institute and a staff member in the Taussig Cancer Institute at Cleveland Clinic.
Advertisement
Related to this article
An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.
Sri Sivalingam, MD, discusses how suction-based technologies are improving stone clearance and raising expectations for ureteroscopic stone treatment.
Based on these results, the trial protocol has been amended to move enrollment earlier in the course of disease progression.
Mark D. Tyson, II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Advertisement
Advertisement